Hemoglobin Nanocrystals for Drugs Free, Synergistic Theranostics of Colon Tumor
Source abstract
Abstract
Abstract The conventional approach in cancer nanomedicine involves advanced drug nanocarriers delivering preloaded therapeutics to targeted tumor sites to maximize drug efficiency. However, both cancer drugs and nanocarriers inevitably produce side effects and systemic toxicity. Herein, hemoglobin nanocrystals (HbC) as drug‐free theranostic nanoformulations with the tumor microenvironment (TME) activated diagnostic and therapeutic abilities towards colon tumors are introduced. HbC can release Fe2+ oxidized to Fe3+ in the Fenton reaction with tumor endogenous H2O2, concurrently with the generation of cytotoxic hydroxyl radicals (•OH) that allow for chemodynamic therapy (CDT). Furthermore, in situ‐produced Fe3+ reacts with colon tumor‐abundant H2S, resulting in the production of Fe1−xS, which provides magnetic resonance imaging (MRI) contrast and allows for NIR light‐inducible photothermal therapy (PTT). In vitro and in vivo studies revealed that HbC produced CDT towards 4T1 tumors, and MRI‐guided, synergistically enhanced combination of CDT and PTT against H2S abundant colon tumors (CT26), with negligible toxicity towards normal tissues, enlightening HbC as highly efficient and biocompatible TME activated theranostic nanoplatform specific against colon cancer without any traditional drugs and drug carriers.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Advanced Nanomaterials in Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Physics and Optoelectronic Engineering Shenzhen Key Laboratory of Photonics and Biophotonics Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province Shenzhen University Shenzhen 518060 P. R. China
Funding
National Natural Science Foundation of China
References (53)
Show source-provided references
1. 10.1016/j.jconrel.2021.08.04910.1016/j.jconrel.2021.08.049 ↗
2. 10.1021/acsami.1c1909610.1021/acsami.1c19096 ↗
3. 10.1021/ja034309510.1021/ja0343095 ↗
4. 10.1021/acsami.0c1404610.1021/acsami.0c14046 ↗
5. 10.7150/thno.3107910.7150/thno.31079 ↗
6. 10.1002/adma.20200110810.1002/adma.202001108 ↗
7. 10.1021/acsnano.5b0770610.1021/acsnano.5b07706 ↗
8. 10.1016/j.bbcan.2021.18862310.1016/j.bbcan.2021.188623 ↗
9. 10.2174/187152062066620092411041810.2174/1871520620666200924110418 ↗
10. 10.1002/adhm.20200147110.1002/adhm.202001471 ↗
11. 10.1002/adma.20170234210.1002/adma.201702342 ↗
12. 10.1002/smll.20190725610.1002/smll.201907256 ↗
13. 10.1016/j.jconrel.2020.11.02610.1016/j.jconrel.2020.11.026 ↗
14. 10.1021/acsnano.1c0047610.1021/acsnano.1c00476 ↗
15. 10.1002/wnan.154710.1002/wnan.1547 ↗
16. 10.1002/smll.20210356910.1002/smll.202103569 ↗
17. 10.1021/acsami.2c0424210.1021/acsami.2c04242 ↗
18. 10.1016/j.actbio.2021.08.05410.1016/j.actbio.2021.08.054 ↗
19. 10.1016/j.biomaterials.2021.12075910.1016/j.biomaterials.2021.120759 ↗
20. 10.1021/acs.nanolett.1c0122010.1021/acs.nanolett.1c01220 ↗
21. 10.1021/acs.biomac.8b0024110.1021/acs.biomac.8b00241 ↗
22. 10.7150/thno.6165110.7150/thno.61651 ↗
23. 10.1016/S0021-9258(17)42604-410.1016/S0021-9258(17)42604-4 ↗
24. 10.1021/jacs.6b0345610.1021/jacs.6b03456 ↗
25. 10.1016/j.bcp.2018.01.04510.1016/j.bcp.2018.01.045 ↗
26. 10.1002/advs.20190351210.1002/advs.201903512 ↗
27. 10.1016/j.cej.2020.12529410.1016/j.cej.2020.125294 ↗
28. 10.1042/CBI2009036810.1042/CBI20090368 ↗
29. 10.1073/pnas.130624111010.1073/pnas.1306241110 ↗
30. 10.1002/anie.20181008210.1002/anie.201810082 ↗
31. 10.1039/C6CE02562E10.1039/C6CE02562E ↗
32. 10.7150/thno.4622810.7150/thno.46228 ↗
33. 10.1016/j.biomaterials.2018.10.00710.1016/j.biomaterials.2018.10.007 ↗
34. 10.1016/0014-5793(86)80626-310.1016/0014-5793(86)80626-3 ↗
35. 10.1021/bi992170y10.1021/bi992170y ↗
36. 10.1006/bbrc.1998.884610.1006/bbrc.1998.8846 ↗
37. 10.1002/2211-5463.1210310.1002/2211-5463.12103 ↗
38. 10.1074/jbc.M115.63983110.1074/jbc.M115.639831 ↗
39. 10.1016/j.cej.2021.13165210.1016/j.cej.2021.131652 ↗
40. 10.1016/j.jallcom.2021.15952210.1016/j.jallcom.2021.159522 ↗
41. 10.1016/j.ccr.2020.21352910.1016/j.ccr.2020.213529 ↗
42. 10.1002/ange.20201537910.1002/ange.202015379 ↗
43. 10.1002/adhm.20200212610.1002/adhm.202002126 ↗
44. 10.1016/j.cej.2021.13009810.1016/j.cej.2021.130098 ↗
45. 10.1016/j.cej.2020.12593310.1016/j.cej.2020.125933 ↗
46. 10.1002/adfm.20160377610.1002/adfm.201603776 ↗
47. 10.1016/j.bios.2015.06.06610.1016/j.bios.2015.06.066 ↗
48. 10.1039/c0an00235f10.1039/c0an00235f ↗
49. 10.1016/j.nano.2013.05.01210.1016/j.nano.2013.05.012 ↗
50. 10.1021/acs.nanolett.2c0134610.1021/acs.nanolett.2c01346 ↗
51. 10.1038/s41467-020-16924-z10.1038/s41467-020-16924-z ↗
52. 10.1021/acsami.1c0533010.1021/acsami.1c05330 ↗
53. 10.3390/nano911154010.3390/nano9111540 ↗